Ophthalmic Comprehensive Reports

2025 Myopia Management Survey Report, December, 2025

Market Scope’s “2025 Myopia Management Survey Report” delivers a comprehensive, provider-level view of how pediatric myopia is being managed in the United States today—examining patient volumes, treatment mix, economics, unmet needs, and how clinical behavior is likely to shift as new therapies reach the market. 

Conducted in August and September 2025, the survey captures insights from 150 US-based optometrists and ophthalmologists, including comprehensive and pediatric specialists actively treating myopia. Respondents were drawn from Market Scope’s self-registered provider community and reflect real-world clinical decision-makers with direct experience in myopia control. 

The report provides a structured summary analysis of de-identified survey data, calculated at the respondent level and presented without market extrapolation to clearly show how providers are thinking, prescribing, pricing, and planning. 

The “2025 Myopia Management Survey Report” delivers granular insight into how many patients providers are seeing, how they are treated, and why certain therapies are—or are not—used. Key areas of coverage include: 

  • Provider Landscape & Patient Volumes: Pediatric patient loads, myopia prevalence (ages 5–17), and the share of patients enrolled in active myopia control programs. 
  • Treatment Adoption & Clinical Strategy: Real-world use of ortho-k, myopia control soft contact lenses, spectacles, and low-dose atropine, including first-line and combination therapy preferences. 
  • Ortho-K Utilization & Economics: Lenses and brands prescribed, annual volumes per patient, pricing and bundling strategies, average patient costs, satisfaction, and adoption barriers. 
  • Low-Dose Atropine Prescribing: Patient and bottle volumes, manufacturer and patient pricing, compliance and adoption barriers, and expected shifts with FDA-approved, preservative-free options. 
  • Myopia Control Soft Contact Lenses: Brand usage, treatment duration, follow-up cadence, compliance challenges, and perceived effectiveness. 
  • Effectiveness, Compliance & Barriers: Provider-rated effectiveness by modality, compliance challenges, and pediatric and adult adoption barriers across treatments. 
  • Pipeline Therapies & Market Evolution: Expected impact, pricing, and duration of use for emerging options, including atropine-eluting lenses and repeated low-level red-light therapy (RLRL). 
  • Technology & Workflow Innovation: Willingness to trust advanced ortho-k fitting software and the factors most likely to drive provider adoption. 

Market Scope conducted the 2025 Myopia Management Survey in the United States during August and September 2025 to assess real-world pediatric myopia management practices and emerging market trends.  

Ophthalmologists and optometrists—including comprehensive and pediatric specialists—who self-registered on Market-Scope.com were invited to participate. Email invitations were distributed on September 5, 2025, with a final reminder sent on September 26, 2025. 

The survey yielded 150 complete, unique responses. All results are presented as a summary analysis of de-identified, provider-reported data and are calculated based on the number of respondents for each question, as applicability varied by provider type and treatment mix.  

No extrapolation beyond the respondent base was performed. Survey questions were developed by Market Scope in collaboration with sponsoring companies, and all data are securely stored and maintained in accordance with Market Scope’s data security standards. 

2 licensing types are available for this report:

  • The price of the single-user license is $7,000.
  • The price of the enterprise license is $10,500 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

  • The Single User License allows for the use of a report by a single user within one corporate location.
  • The report paper copy may not be reproduced (additional paper copies available for purchase).
  • Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
  • Only a single copy of the publication may be printed for internal use.
  • Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

  • The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
  • Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
  • Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
  • Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.

Related Reports

Want to Purchase the Full Report?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.